Minocycline 4% | Niacinamide 3%

Topical cream/gel — apply to affected skin: Cleanse and dry the skin thoroughly before application. Apply a thin, even layer to acne-affected areas or rosacea-involved skin once or twice daily per prescriber direction. Avoid the periorbital area, eyes, and mucous membranes. Wash hands before and after use. Unlike oral minocycline, topical minocycline at 4% achieves negligible systemic absorption, substantially reducing the risk of systemic tetracycline side effects. Allow to absorb before applying other topical products or makeup.

Application frequency and duration are prescriber-determined.

• Typical use: Once or twice daily to affected areas; clinical trials of FDA-approved minocycline foam (1.5%) used once-daily application — compounded 4% concentrations may be used once daily based on prescriber preference.
• Improvement in inflammatory lesion counts typically appears at 4–8 weeks; maximum benefit by 12 weeks of consistent use.
• As with all antibiotic-containing topicals, prescribers should regularly reassess the need for continued use to limit antibiotic resistance development.

• Minocycline 4%: Inhibits bacterial protein synthesis by reversibly binding the 30S ribosomal subunit of susceptible organisms, including Cutibacterium acnes. Beyond antimicrobial activity, topical minocycline exerts potent anti-inflammatory effects by inhibiting matrix metalloproteinases (MMPs), reducing neutrophil chemotaxis, and decreasing inflammatory cytokine (IL-1β, IL-8, TNF-α) expression in the sebaceous follicle — mechanisms particularly relevant to the pathophysiology of inflammatory acne and rosacea. Topical application at 4% achieves follicular drug concentrations sufficient for both antimicrobial and anti-inflammatory effects with minimal systemic exposure.
• Niacinamide 3%: Inhibits PARP-1, reducing NF-κB–mediated inflammatory signaling in keratinocytes. Reduces sebum secretion rates (sebostatic), inhibits melanosome transfer to keratinocytes (reducing post-inflammatory hyperpigmentation), and increases ceramide and free fatty acid synthesis (barrier repair). Bacteriostatic effects against C. acnes have been demonstrated at higher concentrations in vitro.

Indications addressed: Inflammatory acne vulgaris (papulopustular), rosacea (papulopustular subtype), and post-inflammatory hyperpigmentation. The combination is particularly useful in patients who need anti-inflammatory and barrier-repair effects alongside reduction of C. acnes burden.

Prescriber monitoring:

• Assess inflammatory lesion count and erythema at 6–8 weeks
• Monitor for application-site reactions: dryness, erythema, and skin staining (minocycline can rarely cause bluish-gray discoloration of treated skin, particularly with prolonged high-concentration use)
• Counsel on daily photoprotection — tetracyclines are associated with photosensitivity even topically, and acne/rosacea-prone skin is inherently photoreactive
• Reassess antibiotic use at each visit per antibiotic stewardship principles

Contraindications:

• Hypersensitivity to minocycline, tetracyclines, or niacinamide
• Avoid application near eyes or mucous membranes

Warnings & Precautions:

• Photosensitivity: tetracycline derivatives increase UV sensitivity — advise broad-spectrum SPF ≥30 sunscreen daily
• Rare hypersensitivity reactions — discontinue if severe rash, urticaria, or angioedema develops
• Skin pigmentation: prolonged high-concentration topical minocycline may cause blue-gray discoloration at application sites — rare but documented
• Not for use during pregnancy or in children <12 years without specific prescriber direction — systemic tetracycline is contraindicated in these populations; topical absorption is low but not zero

Drug Interactions:

• Systemic antibiotic interactions (e.g., warfarin potentiation) are not expected at topical concentrations but should be considered in patients also receiving oral tetracyclines

Common Side Effects: Application-site dryness, mild erythema, stinging or burning on initial application, contact dermatitis (uncommon); rare: skin discoloration.

Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep tightly capped. Do not freeze. Observe the beyond-use date assigned by Genesis Compounding. Keep out of reach of children and pets.

Why is minocycline being used topically instead of as a pill?

Oral minocycline carries risks of systemic adverse effects including vestibular toxicity (dizziness), skin and mucosal pigmentation, drug hypersensitivity syndrome, and autoimmune reactions. Topical minocycline 4% delivers therapeutic concentrations to the follicle with negligible systemic absorption, targeting the inflammatory lesion directly while minimizing systemic risks.

Will this combination help with dark spots left by acne?

Yes. Niacinamide inhibits the transfer of melanin-containing melanosomes to keratinocytes, reducing post-inflammatory hyperpigmentation (PIH). Minocycline's anti-inflammatory effect also reduces the intensity of the initial inflammatory response that drives PIH.

How long should I use this antibiotic-containing preparation?

Prescribers should reassess the need for continued antibiotic-containing topicals at each follow-up visit. The goal is to achieve inflammatory control and then, if possible, transition to non-antibiotic maintenance. Long-term antibiotic monotherapy increases the risk of resistant C. acnes populations.

Can I use sunscreen over this?

Yes — and it is strongly recommended. Tetracycline-class agents increase photosensitivity; apply a broad-spectrum sunscreen SPF ≥30 after the preparation has absorbed.

Is this combination FDA-approved?

FDA-approved topical minocycline products exist (Amzeeq foam 4%, Zilxi foam 1.5%), but this specific combination with niacinamide 3% is not FDA-approved. It is a prescriber-directed, patient-specific 503A compounded formulation prepared by Genesis Compounding.